Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MM

Multiple Myeloma Clinical Trial

Official title:

Clinical Study to Evaluate the Safety and Feasibility of Targeting CD269 Chimeric Antigen Receptor Engineered T Cell (spCART-269) Injection in the Treatment of CD269-positive Multiple Myeloma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04500431
• Other study ID #: 200802
• Status: Recruiting
• Phase: Phase 1
• Start date: July 1, 2018
• Est. completion date: December 1, 2022

Study information

• Verified date: August 2020
• Source: Shanghai Tongji Hospital, Tongji University School of Medicine
• Contact: Aibin Liang, MD, Ph.D
• Phone: 0086-021-66111019
• Email: lab7182[@]tongji.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The trial is a single arm, single-center, non-randomized phase I clinical trial which is designed to evaluate the safety and efficacy of spCART-269 in treatment of relapsed or refractory multiple myeloma patients.

Description:

This study plans to enroll 10 patients to assess the safety and efficacy of spCART-269. Subjects who meet the eligibility criteria will receive a single dose of spCART-269 injection. The study will include the following sequential phases: Screening, Pre-treatment (Cell product preparation; Lymphodepleting Chemotherapy), Treatment and follow-up.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: December 1, 2022
• Est. primary completion date: July 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. The patient was diagnosed as active MM according to the diagnostic criteria of the International Myeloma Working Group (IMWG)

2. The patient meets any of the following:

1. Have received at least 3 treatment options in the past and include alkylating agents, proteasome inhibitors and immunomodulators;

2. If the patient has received a regimen containing proteasome inhibitor and immunomodulator for at least 2 courses, and the effect is not good (such as disease progression within 60 days of treatment)

3. Voluntary participation in clinical research and signing informed consent

4. Age 18-65, regardless of gender

5. Expected survival time is greater than 12 weeks

6. If the patient has received autologous hematopoietic stem cell transplantation in the past, a 90-day interval is required

7. Normal bone marrow hematopoietic function, blood routine: hemoglobin = 100 g/L; absolute neutrophil = 1.5×10^9/L; platelet count = 100×10^9/L

8. Liver function: serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.5 (ULN) times the upper limit of normal value (if abnormal liver function is mainly caused by tumor infiltration, it can be = 5 times the upper limit of normal value (ULN) )), bilirubin <2.0 mg/dL

9. Renal function: BUN is 9-20 mg/dL, serum creatinine = 1.5 times the upper limit of normal (ULN), endogenous creatinine clearance rate =50 ml/min

10. Serum virus EBV, CMV, HBV, HCV, HIV and syphilis antibodies are negative

11. Heart function: good hemodynamic stability, left ventricular ejection fraction (LVEF) = 45%

12. ECOG physical status score 0-2

13. Possess apheresis or sufficient venous access for venous blood, and no other contraindications for leukocyte separation

14. T cells can be successfully expanded in vitro

15. Women of childbearing age who provide negative reports of pregnancy tests with serum or urine before reinfusion

16. Adults with fertility requirements, regardless of sex, contraception within one year after treatment

Exclusion Criteria:

1. ECOG score = 3 points

2. Female patients during pregnancy or lactation

3. Pathological examination revealed malignant tumor cells with T cell origin

4. Organ failure: Heart failure grade ? and ?; liver reaches Child-Turcotte liver function grade C; renal failure and uremia; respiratory failure; consciousness disorder

5. Patients with acute or chronic GVHD after allogeneic hematopoietic transplantation, or using hormones or immunosuppressants within 30 days

6. Patients with HIV infection or active hepatitis

7. There are other uncontrolled active infections

8. Those who may be allergic to cytokines

9. Those who have used any gene therapy products

10. Those who participated in other clinical studies 4 weeks before enrollment (except those who did not receive treatment in clinical studies)

11. Patients with systemic autoimmune diseases or immunodeficiency diseases

12. Definite neuropathy or psychosis, including authors of dementia or epilepsy

13. Those with lung or intestinal tumor infiltration

14. Patients that other researchers think are not suitable for enrollment

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Biological:
• Targeting CD269 chimeric antigen receptor engineered T cells
Targeting CD269 chimeric antigen receptor engineered T cells, single infusion intravenously

Locations

Country	Name	City	State
China	Shanghai Tongji Hospital, Tongji University School of Medicine	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Tongji Hospital, Tongji University School of Medicine

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrence of study related adverse events	Incidence and severity of Treatment emergent adverse events	12 weeks
Secondary	Overall response rate (ORR)		12 months
Secondary	Duration of remission (DOR)		12 months
Secondary	Progression free survival (PFS)		12 months
Secondary	Overall survival (OS)		12 weeks, 6 months, 12 months